Diamyd Medical announced that 100 patients are now enrolled in the company’s US Phase III study called DiaPrevent at 33 diabetes centers throughout the USA and more sites are to be added. The study will include 320 children and adolescents between 10 and 20 years of age, recently diagnosed with type 1 diabetes.
To date more than 430 children have received Diamyd® or placebo in the global Phase III program with no serious side effects related to the drug reported.
The global Phase III program aims to investigate whether Diamyd® can halt or slow the autoimmune destruction of beta cells in type 1 diabetes, preserving the body’s own ability to control blood sugar levels.
